Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms
Authors:
- Carmela C VittorioCVCarmela C Vittorio
- 1 March 2004
- journal article
- case report
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 50 (3) , 375-379
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Critical roles of PPARβ/δ in keratinocyte response to inflammationGenes & Development, 2001
- Increased interleukin 5 production in eosinophilic S?zary syndrome: Regulation by interferon alfa and interleukin 12Journal of the American Academy of Dermatology, 2001
- Repression of TNF-α-Induced E-Selectin Expression by PPAR Activators: Involvement of Transcriptional Repressor LRF-1/ATF3Biochemical and Biophysical Research Communications, 2000
- The RXR heterodimers and orphan receptorsCell, 1995
- INTRAMUSCULAR LOW DOSE ALPHA‐2B INTERFERON AND ETRETINATE FOR TREATMENT OF MYCOSIS FUNGOIDESInternational Journal of Dermatology, 1993
- Roferon‐A (interferon alpha 2a) combined with tigason (etretinate) for treatment of cutaneous T cell lymphomasStem Cells, 1993
- The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-α2a and etretinateBritish Journal of Dermatology, 1991
- Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoidsJournal of the American Academy of Dermatology, 1991
- Successful treatment of mycosis fungoides with the combination of etretinate and human recombinant interferon alfa-2aJournal of Dermatological Treatment, 1989
- A human retinoic acid receptor which belongs to the family of nuclear receptorsNature, 1987